RxDoctor Payments Data

David Bryson, MD

Ophthalmology · Murray, KYNPI 1841240009

Payments from drug & device makers

$915in general payments, 2019–2025

Across 27 payments — averaging $33.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$320
  • Sight Sciences, Inc.$153
  • Shire North American Group Inc$125
  • Carl Zeiss Meditec, Inc.$65
  • Novartis$42
  • Sun Pharmaceutical Industries Inc.$36
  • plus $174 from 9 others

What the payments were for

  • Food & beverage$915100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$915 in reported general payments places this provider in the 40th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$383,584
Medicare patients
1,335
Services billed
3,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$41,412
LumiganBimatoprost115$41,160
RocklatanNetarsudil Mesylat/Latanoprost92$40,826
XiidraLifitegrast32$28,528
VyzultaLatanoprostene Bunod81$28,475
Cyclosporine46$27,117
CombiganBrimonidine Tartrate/Timolol66$12,389
Travoprost71$7,776
Prednisolone Acetate268$7,002
SimbrinzaBrinzolamide/Brimonidine Tart32$6,456
Timolol Maleate139$6,232
Latanoprost693$5,422
MoxifloxacinMoxifloxacin Hcl171$4,823
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$3,618
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat172$2,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$31$94,961224 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$15$57,003113 claims
AlconSimbrinza$320$6,45632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Murray

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →